Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7223280 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Bacteremia participants without pneumonia and who are not mechanically ventilated at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1. |
| Cohort 2 | EXPERIMENTAL | Participants with hospital-acquired bacterial pneumonia (HABP) and who are not mechanically ventilated at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1. |
| Cohort 3 | EXPERIMENTAL | Participants with mechanical ventilation at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1. |
| Cohort 4 | EXPERIMENTAL | Participants with mechanical ventilation who have a bronchoalveolar lavage (BAL) planned as a part of routine practice will be enrolled in this cohort. Participants will receive RO7223280 on Day 1. |
| Name | Type | Description |
|---|---|---|
| RO7223280 | DRUG | Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1. |
Inclusion Criteria: * Illness requiring treatment in an intensive care unit (ICU) at the time of enrolment * Ongoing clinical syndrome meeting at least one of the following criteria: 1. HABP: bacterial pneumonia diagnosed after more than 48 hours of hospitalization or within 7 days after a hospi...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
RO7223280 is an investigational small molecule developed by Roche Holding AG for the treatment of bacterial infections. It is in Phase 1 clinical development and has been studied in critically ill patients. It is not yet approved for any indication.
RO7223280 is being developed for bacterial infections. Its only completed clinical trial enrolled critically ill participants with bacterial infections to investigate the drug's pharmacokinetics. It remains investigational and is not approved for clinical use.
RO7223280 is developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program evaluating this small molecule for bacterial infections.
RO7223280 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not received FDA approval.
RO7223280 has been evaluated in one completed Phase 1 trial, NCT05614895, titled A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections. The trial enrolled 48 participants across the United States, France, Israel, Moldova, and South Korea.